image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

SEC Filing Details

Document Details

Form
S-1/A
Filing Date
July 23, 2020
Document Date
July 23, 2020
Form Description
Amended Registration statement for face-amount certificate companies
Filing Group
Registration Statements
Company
Nurix Therapeutics, Inc.
Issuer
NURIX THERAPEUTICS, INC.
Print Page
Email Alerts
RSS Feeds
Contact IR